 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 950455-15-9 |
| Molecular formula(MF) | C19H21ClN4 |
| Molecular Weight(MW): | 340.85 |
| Alias |
| In vitro | DMSO | 68 mg/mL (199.5 mM) |
|---|---|---|
| Ethanol | 21 mg/mL warmed (61.61 mM) | |
| Water | <1 mg/mL | |
| In vivo |
| Description | Liproxstatin-1 is a potent ferroptosis inhibitor with an IC50 of 22 nM. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro |
Liproxstatin-1 is able to inhibit ferroptosis in the low nanomolar range and inhibit the growth of Gpx4−/−cells with IC50 of 22 nM. Liproxstatin-1 (50 nM) completely prevents lipid peroxidation in Gpx4−/−cells. Liproxstatin-1 (200 nM) protects against FINs, such as BSO (10 µM), erastin (1 µM) and RSL3 (0.5 µM), in a dose dependent manner, whereas it fails to rescue cell death induced by staurosporine (0.2 µM) and H2O2 (200 µM).[1] |
||
| In vivo | Liproxstatin-1 remarkably extends survival compared with the vehicle-treated group, delays ferroptosis in tubular cells, and mitigates tissue injury in ischaemia/reperfusion-induced liver injury. [1] |